Magnetic resonance imaging of primary malignant bone tumors.

Bloem, Johan L.; Falke, T H; Taminiau, A. H. M.; Doornbos, J; Oosterom, A.T. van; Steiner, R M; Overbosch, E E; Plantes, B. G. Ziedses des

doi:10.1148/radiographics.5.6.3880008

Cited by 20 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kumar and Hari conducted a prospective study on 50 patients with suspected primary malignant bone tumors and found 86% of the tumors had a cortical break identified on their MRI (21). Bloem et al conducted a study in 53 patients with primary malignant bone tumors and found cortical destruction in 23 cases (22) and found cortical destruction in 54 of 92 quadrants when dividing each bone lesion into four quadrants circumferentially. In addition, they also reported that MRI was more sensitive than CT in detection of cortical destruction.…”

Section: Discussionmentioning

confidence: 99%

Magnetic resonance imaging in differentiating between aggressive and non-aggressive bone tumors

et al. 2022

View full text Add to dashboard Cite

Background While radiography remains essential in the initial evaluation of bone lesions, tissue biopsy or further imaging is often required to clarify indeterminate radiographic features. Magnetic resonance imaging (MRI) assists radiologists in evaluating lesions with indeterminate features as it has advantages in delineating tumorous tissues and bone marrow. Purpose To evaluate the association factors of MRI for bony aggressiveness. Material and Methods A retrospective analysis of 226 MRI examinations from patients diagnosed with bone tumors in a tertiary hospital during 2008–2018 was performed. All the MR images were interpreted by musculoskeletal radiologists without diagnostic information. The bony lesions were categorized into aggressive and non-aggressive groups using tumor margin, cortical changes, periosteal reaction, joint extension, extraosseous soft tissue involvement, tumor homogeneity, and enhancement pattern from the MR images. Univariable and multivariable analysis were applied for each feature on the MRI scans. In addition, sensitivity and specificity were calculated for MRI diagnoses of aggressive bone lesions. Results In total, 180 aggressive and 46 non-aggressive bone lesions were examined on MRI. The sensitivity and specificity of MRI for differentiating between aggressive and non-aggressive bone lesions were 98.89% and 50%, respectively. Ill-defined margin, cortical break, cortical signal changes, sunburst and Codman's triangle periosteal reaction, joint extension, and tumoral and heterogeneous enhancement could be predictive signs for aggressive bone lesions. Conclusion MRI can be a valuable tool to assist in distinguishing aggressive from non-aggressive bone lesions. In cases of indeterminate radiographic features, MRI could be used as an additional imaging to improve diagnostic accuracy and could reduce unnecessary invasive procedures.

show abstract

Section: Discussionmentioning

confidence: 99%

Magnetic resonance imaging in differentiating between aggressive and non-aggressive bone tumors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Computed tomography (CT) and magnetic resonance imaging (MRI) are more frequently used in the diagnosis of malignant bone tumors [ 26 , 27 ]. MRI is mainly used to determine the local extent and surgical stage of a malignant bone tumor [ 28 ], which is critical to the operative design for tumor resection [ 29 , 30 ]. High resolution CT-imaging can aid surgeons in grading malignant bone tumors and detecting initial metastatic lesions [ 31 , 32 ].…”

Section: Primary and Secondary Bone Cancersmentioning

confidence: 99%

Bifunctional bone substitute materials for bone defect treatment after bone tumor resection

Wang,

Geest,

Leeuwenburgh

et al. 2023

Materials Today Bio

View full text Add to dashboard Cite

“…Le scanner peut ê tre utile pour la dé tection des calcifications, l'é tude fine du pé rioste, les mesures de densité , mais l'IRM reste l'examen de choix pour le bilan local d'extension en particulier dans les parties molles [5]. Elle devra concerner l'inté gralité de l'os y compris articulations sus-et sous-jacentes pour é valuer l'extension en hauteur et é liminer des skips mé tastases.…”

Section: Diagnostic Et Bilan Initialunclassified

Ostéosarcomes de l’enfant

Marec‐Bérard

Chotel

2006

Oncologie

View full text Add to dashboard Cite

Ré sumé : La prise en charge des enfants atteints d'osté osarcome a nettement é volué depuis 30 ans grâ ce à l'avè nement des polychimiothé rapies, aux progrè s des techniques d'imagerie, et à l'amé lioration des techniques chirurgicales, en particulier les techniques conservatrices. La survie à cinq ans est passé e de 20 % avec l'amputation seule à plus de 70 % actuellement. Le traitement standard actuel consiste en une chimiothé rapie né oadjuvante, suivie d'une chirurgie le plus souvent conservatrice (80 % des cas) puis d'une chimiothé rapie adjuvante. Les protocoles associent anthracyclines, ifosfamide, cisplatinum, é toposide ainsi que mé thotrexate haute dose chez l'enfant. La ré ponse histologique à la chimiothérapie reste le principal facteur pronostique qui permet d'adapter le traitement postopé ratoire. La prise en charge de cette pathologie impose une certaine expé rience et une dé marche diagnostique et thé -rapeutique rigoureuse. Les patients atteints d'osté osarcomes doivent ê tre pris en charge dans des centres spé cialisé s par des é quipes multidisciplinaires afin de bé né ficier d'un maximum de chances de gué rison avec un minimum de sé quelles. Mots clé s : Osté osarcome -EnfantThé rapeutiqueOsteosarcoma in children Abstract: Major advances have been made over the past 30 years in the treatment of children with osteosarcoma. This was possible especially with the use of polychemotherapies, the development of imaging devices, and the improvement of surgical techniques (particularly for conservative surgery). The five-year survival rate of these patients has increased from 20% with surgery alone, to over 70% at present. Current standard treatments involve neoadjuvant chemotherapy, followed by surgery (80% of which being conservative surgery), then adjuvant chemotherapy. Chemotherapy protocols combine antracyclins, ifosfamide, cisplatinum, etoposide and high-dose Methotrexate. The major prognostic factor is the histological response to chemotherapy, which is used to determine post-operative care. The successful treatment of osteosarcomas depends on a strict diagnosis and a treatment delivered by experienced practitioners. Only osteosarcoma patients treated in specialized centres by multidisciplinary teams have the greatest chance of being cured with a minimum of sequels.

show abstract

Magnetic resonance imaging of primary malignant bone tumors.

Cited by 20 publications

References 0 publications

Magnetic resonance imaging in differentiating between aggressive and non-aggressive bone tumors

Magnetic resonance imaging in differentiating between aggressive and non-aggressive bone tumors

Bifunctional bone substitute materials for bone defect treatment after bone tumor resection

Ostéosarcomes de l’enfant

Contact Info

Product

Resources

About